[gwerbret]

This was a Phase 1 study, which means that it was designed exclusively to test safety and tolerability of the agent. This explains both the small sample size and the crossover design. I wouldn't expect there to be even tentative assessment of effect until they run a larger Phase 2 trial. As for the press office, all it would know (or care) is that this was published in a decent journal.

[wpietri]

If that's what the press office knows, "A pill that staves off aging? It's on the horizon" is a ridiculously overblown title.